This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

This study has been completed.
Information provided by (Responsible Party):
Mirati Therapeutics Inc. Identifier:
First received: May 14, 2008
Last updated: January 6, 2015
Last verified: January 2015
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.

Condition Intervention Phase
Advanced Malignancies Drug: MGCD265 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Further study details as provided by Mirati Therapeutics Inc.:

Primary Outcome Measures:
  • Safety and tolerability [ Time Frame: 1 year [Anticipated] ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: 1 year [Anticipated] ]
  • Pharmacodynamics [ Time Frame: 1 year [Anticipated] ]
  • Clinical response [ Time Frame: 1 year [Anticipated] ]

Enrollment: 47
Study Start Date: April 2008
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: MGCD265
Oral daily administration; 7 days on / 7 days off

Detailed Description:

MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients.

In this study, oral MGCD265 is administered daily on a 7 days on / 7 days off schedule to patients with advanced malignancies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with advanced metastatic or unresectable malignancy that is refractory to standard therapy and/or existing therapies are not likely to achieve clinical benefit. The patient's disease must be histologically confirmed;
  • Evaluable disease;
  • Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least 4 weeks before the start of therapy on Cycle 1 Day 1;
  • Recovery from the adverse effects of prior therapy at the time of enrollment to ≤ grade 1 (excluding alopecia);
  • Age ≥ 18 years;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;
  • Life expectancy greater than 3 months following study entry;
  • Adequate renal function;
  • Adequate hepatic parameters;
  • Adequate bone marrow function;
  • A negative serum pregnancy test at screening for women of childbearing potential (WOCBP);
  • Agreement by WOCBP or men whose sexual partners are WOCBP to use two methods of adequate contraception hormonal and barrier method) prior to study entry and for the duration of the study. WOCBP and men whose sexual partners are WOCBP must continue to use two methods of contraception for 28 days and 90 days, respectively, after the last dose of study medication;
  • Ability to understand and willingness to sign a written informed consent document;
  • Willingness and ability to comply with study visits and activities to be performed only at the study center; and
  • For the Expanded MTD Cohort, the subject must have tumors that are accessible to biopsy.

Exclusion Criteria:

  • Subjects with uncontrolled concurrent illness;
  • Subjects with a history of a cardiovascular illness;
  • Subjects with QTc > 470 msec (including subjects on medication);
  • Subjects with left ventricular ejection fraction (LVEF) < 50%;
  • Subjects with leukemias or myelodysplastic syndrome;
  • Immunocompromised subjects;
  • Subjects with a history of autologous bone marrow transplant (BMT) within the previous five years, or subjects with organ transplants or allogeneic BMT;
  • Subjects with lung tumor lesions with increased likelihood of bleeding, including: history of hemoptysis; evidence of cavitation; and invasion of aorta or pulmonary arteries by the tumor;
  • Subjects with a history of brain metastasis or leptomeningeal disease; subjects with tumors likely to metastasize to the brain should have a scan performed within 2 months of start of study to rule out brain metastasis (for example breast, lung, melanoma, sarcoma, etc.);
  • Subjects unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs;
  • Subjects with a history of major surgery within 28 days of first receipt of study drug;
  • Nursing or pregnant women;
  • Subjects with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the opinion of the Investigator, contraindicates the use of MGCD265 Drug Product or that may render the subject at excessively high risk for treatment complications; or
  • Subjects with a known hypersensitivity to any of the components of the MGCD265 Drug Product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00679133

United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Mirati Therapeutics Inc.
Study Director: Manuela Juretic MethylGene Inc.
  More Information

Responsible Party: Mirati Therapeutics Inc. Identifier: NCT00679133     History of Changes
Other Study ID Numbers: 265-102
Study First Received: May 14, 2008
Last Updated: January 6, 2015

Keywords provided by Mirati Therapeutics Inc.:
Phase 1

Additional relevant MeSH terms:
Neoplasms processed this record on September 21, 2017